The FDA is reviewing risperidone (Uzedy) extended-release injectable suspension for maintenance treatment of adults with ...

The application leverages existing clinical data for Uzedy along with prior FDA findings on the safety of Udezy in patients ...

Christophe Douat, CEO, and Richard Malamut, CMO, will present Medincell’s corporate overview at the TD Cowen 45 th Annual Healthcare Conference on Monday, March 3, 2025, at 9:50am ET. Live webcast and ...

Teva Pharmaceuticals (TEVA) and Medincell (MEDCL) announced that the supplemental New Drug Application sNDA for UZEDY extended-release ...

Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and Medincell announced that the supplemental New Drug ...

Israel-headquartered Teva Pharmaceutical Industries’ US subsidiary and France’s and Medincell announced that the supplemental ...

Medincell (Paris:MEDCL): This press release is not being made in and copies of it may not be distributed or sent, directly or indirectly, into the United States, Australia, South Africa, Canada or ...

The Global Offering, for approximately 10% of the Company’s share capital, is aimed at international institutional investors, via a Private Placement through an accelerated book-building process. The ...

The FDA has accepted a supplemental New Drug Application submitted by Teva (NYSE:TEVA) and Medincell (OTC:MDCLF) for Uzedy ...

Funds raised will enable Medincell to strengthen licensing opportunities by expanding BEPO® technology’s reach into new molecules and indications, and potentially by potentially considering ...

UZEDY is currently approved for use every one or two months as a subcutaneous long-acting injectable (LAI) for the treatment ...